Abbvie and Genmab Announce Antibody Collaboration Worth Over $3.1 Billion
The companies have entered into a collaboration agreement to develop and commercialize three of Genmab's early-stage investigational bispecific antibody product candidates.
Abbvie and Genmab announced on June 10, 2020 that they have entered into a collaboration agreement worth over $3.1billion to develop and commercialize three of Genmab's early-stage investigational bispecific antibody product candidates.
Under the terms of the agreement, Genmab will provide an upfront payment of $750 million with potential milestone payments of up to $3.1 billion, an Abbvie press release said. The companies will share commercial responsibilities for each antibody product candidate in the United States and Japan. The agreement also allows for the companies to enter into a discovery research collaboration for future differentiated antibody therapeutics for cancer.
The companies plan to develop Genmab's next-generation bispecific antibody programs, epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37, and DuoBody-CD3x5T4, according to the press release. Additionally, through the discovery research collaboration, the companies will combine their proprietary antibodies along with Genmab's DuoBody technology and AbbVie's payload and antibody drug conjugate technology to select and develop up to four added differentiated next-generation antibody-based product candidates
"This transformative collaboration will allow us to accelerate, broaden and maximize the development of some of our promising early-stage bispecific antibodies, including epcoritamab, with the ultimate goal of bringing these potential therapies much faster to cancer patients," said Jan van de Winkel, PhD, CEO of Genmab, in the press release. "Today's announcement marks the beginning of a new journey for Genmab that combines our world-class knowledge in antibody biology and deep expertise in truly innovative next-generation antibody technology platforms, with AbbVie's R&D prowess and their leadership position in hematological cancers."
"Epcoritamab is a strong fit for our robust hematological oncology franchise,” said Michael Severino, MD, vice-chairman and president, AbbVie, in the press release. "By combining the strengths of our two organizations, we can advance the treatment landscape for patients battling cancer."
Source: Abbvie
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
